Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting

The latest announcement is out from Kyverna Therapeutics, Inc. ( (KYTX) ).

On May 29, 2025, Kyverna Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, where approximately 70.67% of the outstanding shares were represented. During the meeting, stockholders elected Beth Seidenberg, M.D. and Fred E. Cohen, M.D., D. Phil. as Class I directors to serve until the 2028 annual meeting. Additionally, the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.

The most recent analyst rating on (KYTX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.

Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Average Trading Volume: 308,546

Technical Sentiment Signal: Sell

Current Market Cap: $114.5M

See more insights into KYTX stock on TipRanks’ Stock Analysis page.